Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 2/20 | 0.39 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.39 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.39 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.39 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.39 |
| ▸ | BRD4 | O60885 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | PPM1B | O75688 | 1/20 | 0.33 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.33 |
| ▸ | PPP1CC | P36873 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22645249 | 0.79 | POLB (0.39) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL12499893 | 0.78 | — | — | |
| SCHEMBL1867430 | 0.78 | LMNA (0.42) | ALDH1A1PPM1BPTPN1PPP1CC | |
| SCHEMBL12191578 | 0.77 | — | — | |
| SCHEMBL15804441 | 0.77 | APLNR (0.33) | TP53SMN1; SMN2 | |
| SCHEMBL17540952 | 0.76 | ALDH1A1 (0.36) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL1487144 | 0.75 | L3MBTL1 (0.35) | ALDH1A1PPM1BPTPN1PPP1CCKMT2A | |
| SCHEMBL393713 | 0.75 | L3MBTL1 (0.35) | ALDH1A1PPM1BPTPN1PPP1CCKMT2A | |
| SCHEMBL877770 | 0.75 | L3MBTL1 (0.35) | ALDH1A1PPM1BPTPN1PPP1CCKMT2A | |
| SCHEMBL5532753 | 0.75 | APLNR (0.48) | TP53SMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11008312-B2 | Pyridazine derivatives as RORc modulators | GENENTECH, INC. (US) | 2021-05-18 | — | — | US | disclosed |
| US-11008312-B2 | Pyridazine derivatives as RORc modulators | GENENTECH, INC. (US) | 2021-05-18 | — | — | US | disclosed |
| EP-3535255-A1 | PYRIDAZINE DERIVATIVES AS RORC MODULATORS | H. Hoffnabb-La Roche Ag (CH) | 2019-09-11 | — | — | EP | disclosed |
| US-20190263794-A1 | PYRIDAZINE DERIVATIVES AS RORc MODULATORS | GENENTECH, INC. (US) | 2019-08-29 | — | — | US | disclosed |
| US-20190263794-A1 | PYRIDAZINE DERIVATIVES AS RORc MODULATORS | GENENTECH, INC. (US) | 2019-08-29 | — | — | US | disclosed |
| WO-2012076989-A1 | KETOLIDE COMPOUNDS | WOCKHARDT LIMITED (IN) | 2012-06-14 | — | — | WO | disclosed |
| EP-0643055-B1 | Proces for the preparation of 5-amino-2,2-dialkyl-1,3-dioxanes | ZAMBON SPA (IT) | 1997-10-08 | — | — | EP | disclosed |
| US-5580993-A | Process for the preparation of iopamidol and 5-amino-2,2-dialkyl-1,3-dioxanes | ZAMBON GROUP S.P.A. (IT) | 1996-12-03 | — | — | US | disclosed |
| EP-0643055-A1 | Proces for the preparation of 5-amino-2,2-dialkyl-1,3-dioxanes | ZAMBON GROUP S.p.A. (IT) | 1995-03-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11008312-B2 | Pyridazine derivatives as RORc modulators | RORC, RORB, RORA | CHRNB2 718/4885CHRNA4 510/4885CHRNB4 831/4885 |
| US-20190263794-A1 | PYRIDAZINE DERIVATIVES AS RORc MODULATORS | RORC, RORB, RORA | CHRNB2 718/4885CHRNA4 510/4885CHRNB4 831/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.